Short answer
Kyverna Therapeutics Inc (KYTX) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$42M
- −14.0% YoY · −9.5% QoQ
- EPS (diluted)
- −$0.67
- +20.2% YoY · −6.3% QoQ
Source: XBRL data from the Kyverna Therapeutics Inc (KYTX) Q3 2026 10-Q on SEC EDGAR. USD.
Kyverna Therapeutics Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, with no approved products or product sales
- Net loss $41.9M vs $36.8M YoY, operating loss $42.9M vs $38.7M
- R&D $27.0M, down 11%; G&A $15.9M, up 92%, worst cost trend
- Cash, equivalents and marketable securities $170.6M; nine-month operating cash use $117.3M
- SPS BLA completed in fourth quarter 2026, potential 2027 launch; funding expected for at least 12 months
Risk Factors
- New legal risk: securities class action survived dismissal of Sections 11 and 15 claims on October 20, 2026
- Regulatory risk: FDA CAR-T malignancy investigation could require boxed warnings, lifetime monitoring, or added post-approval obligations
- Operational risk: miv-cel BLA submitted in fourth quarter 2026, but FDA acceptance and approval remain uncertain
- Financial risk: $120.0 million nine-month net loss and $544.8 million accumulated deficit require substantial additional capital
- Competitive risk: miv-cel faces approved therapies including Rituxan and Ocrevus plus emerging CAR-T and T-cell engager treatments
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.